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Abstract
Background: For a clinical trials unit to run its first model-based, phase I trial, the statistician, chief investigator, and
trial manager must all acquire a new set of skills. These trials also require a different approach to funding and data
collection.
Challenges and discussion: From the statisticians’ viewpoint, we highlight what is needed to move from running
rule-based, early-phase trials to running a model-based phase I study as we experienced it in our trials unit located
in the United Kingdom. Our example is CHARIOT, a dose-finding trial using the time-to-event continual reassessment
method. It consists of three stages and aims to discover the maximum tolerated dose of the combination of radiotherapy,
chemotherapy, and the ataxia telangiectasia mutated Rad3-related inhibitor M6620 (previously known as VX-970)
in patients with oesophageal cancer. We present the challenges we faced in designing this trial and how we
overcame them as a way of demystifying the conduct of a model-based trial in a grant-funded clinical trials unit.
Conclusions: Although we appreciate that undertaking model-based trials requires additional time and effort,
they are feasible to implement and, once suitable tools such as guiding publications and document templates
become available, the design and set-up process will be easier and more efficient.
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Background
Phase I clinical trials comprise a significant part of a
clinical trials unit’s portfolio, particularly in the cancer
community, as they test the first administration of a single
agent or combination of agents to humans. These trials
aim to identify the maximum tolerated dose (MTD),
which is the dose that does not cause dose-limiting toxic-
ities (DLT) above the target toxicity level (TTL). They are
either algorithm-based, such as the 3 + 3 or model-based,
such as the continual reassessment method (CRM).
Over the past several decades, most phase I studies
have used a 3 + 3 design or one of its modifications. The
3 + 3 enrols cohorts of three patients at a time. The first
cohort is treated at a starting dose that is considered to
be safe. If at least one of these patients experiences a
DLT, a second cohort of three patients is assigned to the
same dose level. Otherwise, the second cohort is treated
at the next, higher dose level. The dose escalation pro-
ceeds until at least two of six patients (33%) experience a
DLT at a given dose level. The dose level just below this
level is then recommended for further exploration. The
many modifications of the 3 + 3 design have relaxed some
of its rules, but all forms make dose-escalation decisions
by considering the previous three to six patients.
In contrast, model-based designs estimate the dose-
toxicity relationship with a statistical model, and use this
model to allocate patients to doses and find the MTD. Data
from all enrolled (completely and partially followed up)
patients are used to continuously update the dose-toxicity
model. This model guides every dose-allocation decision
and therefore results in a more accurate estimate of the
MTD. An advantage of model-based designs is that more
patients are treated near the MTD without exposing them
to additional risk [1].
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One of the modifications to the initial CRM design, pub-
lished in 2000, is the time-to-event continual reassessment
method (TiTE-CRM) [2]. This design allows late-onset
toxicities to be accounted for without fully observing a
patient before recruiting the next, and uses all accumulated
information to recommend each dose. As we do not have
to wait until complete follow-up, the overall trial duration
is shortened. This is a step change for radiotherapy trials,
where toxicity follow-up is often 3–6 months. Having
to pause recruitment while the current cohort is fully
followed up makes traditional methods infeasible and
from a trial management perspective also cumbersome.
CHARIOT is the first trial in our grant-funded clinical
trials unit using a TiTE-CRM design. Until this time, we
had been unable to convince clinicians to use a model-
based design but the benefits in this trial due to the late-
onset toxicities outweighed any resistance. In this article,
we describe the development of the UK trial CHARIOT as
experienced by the trial statisticians; from initial discussions
with the chief investigator (CI) to securing funding and
writing the trial protocol and statistical analysis plan. We
discuss the design and characteristics of CHARIOT (see
Trial example), present the challenges we faced and diffi-
culties we overcame to build an efficient and robust model
framework (see Challenges/features), and summarise our
learning (see Discussion and Conclusions).
Trial example
CHARIOT is a single-arm open-label, phase I dose-
escalation trial and is the first trial examining the combin-
ation of radiotherapy, chemotherapy, and the ataxia tel-
angiectasia mutated Rad3-related (ATR) inhibitor M6620
(previously known as VX-970) in patients with oesophageal
cancer. The aim is to identify the maximum tolerated
schedule associated with no more than a predefined TTL.
CHARIOT consists of three stages, each with a different
TTL. Although each stage is characterised by its own set
of inclusion/exclusion criteria, number of treatment sched-
ules, and treatment duration, we used the same approach
to choose the trial specifications, including the DLTs and
TTLs, in all three.
Figure 1 outlines the main characteristics of each stage.
Stage A1 will address patients with oesophageal cancer
receiving palliative radiotherapy. There will be three
frequencies of administering M6620 and two doses, giving
six treatment schedules of interest. The dose and frequency
of radiotherapy will remain constant. The setting for stage
A2 will be patients with any solid tumour receiving only
chemotherapy. Two doses of M6620 will be tested at
weekly and twice-weekly frequencies, giving four treatment
schedules.
Once we have enough information from stages A1 and
A2, the M6620 will be tested in stage B. It will be adminis-
tered in combination with cisplatin, capecitabine, and
radical radiotherapy to identify the MTD, which will be
taken forward in future phase II studies. The patients in
stage B will have oesophageal cancer amenable to radical
treatment. Six treatment schedules will be tested. The
frequency of administration of M6620 differs across the
different schedules. The dose of M6620 at each adminis-
tration will not change and will be informed by the results
of stages A1 and A2.
We assume that as the schedule number increases,
toxicity and efficacy increase as well (monotonicity assump-
tion). Modelling only the schedule and toxicity relationship
via a dose-toxicity curve is therefore sufficient. As the DLT
assessment windows in each stage are long (Fig. 1), a
TiTE-CRM design will be used in all three stages to
find the optimal treatment schedule.
As a model-based design, TiTE-CRM allows us to
tailor the trial to the CI’s requirements. For example, as
CHARIOT is the first trial exploring these lines of
Fig. 1 Set-up of CHARIOT – this schema outlines the main characteristics of the three stages in CHARIOT
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treatment, the CI requests to treat the first three patients
on the lowest treatment schedule and observe them for the
entire DLT window before recruiting the next patient. This
will provide insights into the profile of the radiotherapy
and M6620 combination. As we also want dose escalation
to be fairly rapid, we will use cohorts of one and make
dose-allocation decisions every time a patient is recruited.
The trial design ensures:
– schedule allocation for each newly recruited patient
after the first three patients are fully followed-up;
– no treatment schedule skipping on escalation for
untried schedules;
– no restriction on treatment schedule de-escalation;
– the treatment schedule assigned will be that
estimated to be closest to, but not above, the MTD;
– a safety stopping rule will restart the trial using a lower
dose of M6620 or terminate when sufficient evidence
suggests that the lowest schedule is overly toxic. We
will consider the lowest schedule to be too toxic if,
given all available data, there is a high probability
(95%) that the DLT rate is greater than the TTL;
– early stopping for success when an adequate number of
patients has been treated at a dose level where we define
“success” to mean stabilisation of the MTD estimate;
– recruitment slots will be used to ensure enough
information is accumulated to inform the best
assignment of the treatment schedule to a patient.
The clinical trials unit will inform recruiting sites
when a slot becomes available and the window in
which treatment should begin. For example in A2, as
soon as the patient starts treatment the next slot can
be made available, maximising recruitment whilst
allowing an appropriate review period for the previous
patient. Further, to enable recruitment, two slots will
be available at any point when there is more than
4 weeks since the previous patient started treatment;
– stage A1 and stage A2 to run in parallel.
Each escalation decision will be made by the trial
management group (TMG), consisting of the CI, the
principal investigators, the trial manager, and the trial
statisticians, and will be based on the recommendation
of the TiTE-CRM model and the accumulated experience
with the treatment. If the TMG disagrees with the model’s
recommendation to escalate or a stopping rule has been
met, an independent data safety and monitoring committee
will review the decision. This independent committee will
include at least one model-based design expert.
Challenges/features
The challenges faced during the set-up of CHARIOT are
not presented in a strictly hierarchical order; going back
and forth was part of the learning process.
Communication within the trial team
Communication between the statisticians, the CI and
the rest of the clinical trial unit’s staff was key during the
early stages of the set-up process. Meetings were required
to ensure the defined treatment schedules were nested, the
monotonicity assumption was satisfied, and stopping rules
for success and safety were established. The CI needed to
specify the skeleton, which is the level of toxicity she might
expect to see on each treatment schedule. This is a
challenging task, which she was facing for the first time.
She initially found the task daunting, but reviewing the
literature, discussing the issue with fellow clinicians, and
trying to put toxicity expectations into numbers resulted in
reasonable prior probabilities. Deciding on an acceptable
TTL was another new task facing the trial management
team. Other discussions included how to use data from the
first two stages to inform the final stage, when to start the
final stage, and how to shorten the entire trial duration.
Statistical programming
CRM and TiTE-CRM have been implemented in various
statistical software packages. However, code was not avail-
able to accommodate all of the trial’s characteristics, such as
a pause in recruitment after the first three patients; a delay
between recruitment and assigning a dose level in stage B,
as all patients will receive the same treatment for the first
6 weeks; different time-to-event toxicity distributions; dose-
escalation rules that do not allow overdosing based on the
accumulated information; and early stopping rules.
Two trial statisticians therefore independently developed
programs for executing and simulating the trial and for
processing their results using R and OpenBugs. Writing
our own code helped us to understand the underlying
mechanisms of the method. Writing two versions allowed
us to validate the statistical programs before executing on
real data, which is a requirement of our unit’s standard
operating procedures. Due to the complexity of the code,
additional time was allowed for debugging.
We decided important trial properties and characteristics,
like the skeleton, escalation rules, stopping rules, and
sample size, by combining clinical expertise with results
from a range of simulation scenarios.
Simulations
Simulations played an integral role in designing CHARIOT.
They facilitated understanding of the mechanics and
behaviour of the model under a range of circumstances
and led the selection of specific design characteristics
appropriate for CHARIOT. We simulated trials with
different early stopping rules, maximum sample sizes, DLT
distributions, and dose-escalation rules. The simulation
properties are given in more detail in Table 1.
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For each set of design rules, we checked the properties
of the trial under different toxicity distributions, which
were chosen to reflect realistic and extreme scenarios.
Figure 2 presents the scenarios explored for stage A1.
We ran 1000 simulations for each toxicity distribution
and design rule. The OpenBugs model ran for 10,000
iterations for each simulation, of which 1000 were set as
burn-in. Simulations of each scenario gave us operating
characteristics such as the number of times each schedule
was selected as the MTD, the average number of patients
treated on each schedule, the sample size, and the trial
duration. We then used these operating characteristics to
guide our choice of a design with the best properties.
Discussing simulation results with non-statistical team
members helped them to understand the CRM design.
By simulating single trials and working through them
step by step, we were able to show how dose decisions
would be made during the trial.
Trial management
The TiTE-CRM requires maximum data capture to
make the most accurate recommendation. This requires
participating sites to provide real-time data for every
participant just prior to the TMG meeting. To facilitate
this, we developed a dedicated case report form (CRF)
requiring only data essential to the execution of TiTE-
CRM code. If tight timelines dictate a TMG to be held
without much notice, data can be communicated through
the telephone and the code can be executed during the
meeting. As the information being presented to the TMG
is novel and differs considerably from traditional “3 + 3”
escalation procedures, the trial management team decided
to hold a mock TMG meeting using dummy data prior to
the recruitment of the first patient.
To enable the clinicians to plan for the TMG, as treatment
generally starts on a Monday, we plan to hold a TMG
meeting every Wednesday which will occur only if a
participant has been recruited. This would allow enough
time to prepare the prescription and to deal with any
issues arising from the dose recommendation being rejected
by the TMG.
Radiotherapy DLTs can have a late onset and we want
to assign dose with maximum accumulated data on each
patient. It is, therefore, critical to report all DLTs promptly.
To achieve this we decided to report all DLTs using the
serious adverse event (SAE) reporting system which is
familiar and robust. This will ensure that the CI and TMG
will know about the occurrence of a DLT within 24 hours
of the site being aware.
As total drug requirements could not be known in
advance, we produced two forecasts. The first assumes
that all treatment schedules are recommended and the
maximum number of patients is required to complete
the study. The second forecast is based on the simulation
results. Both forecasts were provided to the pharmaceutical
company supplying M6620 to show drug requirements
and cost under two plausible scenarios.
Funding
Funding for statistics work was required for two periods
of the trial design process. Considerable work was needed
before the grant application, and this statistical time was
funded from local resources. Funding for statistics input
during the trial set-up was requested in the grant applica-
tion. Although the trial design was received well by the
funding body, they questioned “why funding for a statistician
Table 1 Design characteristics for simulations
Design characteristic Specifics
Stopping rule 6, 8, 10 patients on a dose, no early stopping
Maximum sample size Stages A1 and A2: 15, 20, 25, Stage B: 20, 25, 30
Distribution of toxicities Uniform, triangular with the mode half-way
through the dose-limiting toxicity window
Dose escalation With or without overdosing allowed
Dose allocation No dose skipping when escalating but no
restrictions in de-escalating
Accrual rate (patient/weeks) 1/4, 1/6, 1/8






















Fig. 2 Simulation scenarios explored for stage A1 – the black solid
line shows the skeleton (also explored as a scenario). The coloured
solid lines define the dose toxicity curve that we simulated data
from. The black dashed line shows the target toxicity level (TTL)
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is needed for a phase I trial”. We were fortunate to be able
to fund the statistical input from local resources.
In future grant applications we plan to move as much
of the statistical input for design into the trial set-up
period, and therefore within a grant, as possible. A trial
design must be named when applying for a grant, but
time can be allocated in the application to finalise the
design parameters. We also note that there are trial
design funding opportunities via the UK Joint Global
Health Trials scheme (UK Department for International
Development (DFID), Medical Research council (MRC),
National Institute for Health Research (NIHR), Wellcome
Trust) and the US National Institutes of Health (NIH). As
we design more such studies we build up experience and
template documents to speed the set-up process.
Manpower and lead time
As CHARIOT was our unit’s first trial using TiTE-CRM,
between two and three statisticians were assigned to
work on the trial, familiarise themselves with the method
through self-study, courses, and seminars, and, ultimately,
ensure that the TiTE-CRM design could meet the CI’s
expectations. External advice was also sought through the
Methodology Advisory Service for Trials (MAST) of the
MRC Hubs for Trials Methodology Research [3].
Discussion
When we set out to design our first TiTE-CRM trial,
our unit only had experience in running A + B trials. We
therefore faced a steep learning curve. The planned trial
requires three stages, has a long toxicity period, and
tests treatment schedules rather than a single drug at
different doses. We discovered that discussing the TTL
and prior toxicity probabilities of each schedule during
design meant that the whole trial team started the trial
more aware of the expected toxicity than would usually
be the case in a phase I trial.
Support from experienced statisticians via the MRC
Methodology Hubs and MAST [3] was essential in setting
up this trial. As interest in implementing model-based
trials is growing, the NIHR is trying to facilitate the use of
CRM by showing how the barriers to these designs can be
overcome [4].
The European regulatory guidance on first-in-man
trials [5] does not dictate a design [6–9] and our ethics
committee and the funder were both supportive of the
planned design.
As a grant-funded clinical trials unit, we were fortunate
to be able to fund the design stage of our first TiTE-CRM
trial from local resources. As we did not know how much
statistical detail should be included in a model-based trial
grant application, preparing the grant application took
longer than anticipated. We ran lots of simulations and
had many meetings with the trial management team about
the design, so that we had a full trial design when we
applied for the grant. However, we have learnt that many
of these details could have been finalised during trial
set-up, after funding had been received. In future grant
applications, we will leave the finer details of the design
for later in the process and will instead simply describe
the trial in broad and lay terms.
With the benefit of a deeper understanding of TiTE-
CRM, we now realise that investing time in testing some
aspects of the design, such as pausing recruitment after
the first cohort to look at safety, does not affect the
model’s results or performance. However, code is still
needed to test different escalation rules. We appreciate
that first trials of any design are particularly hard to fund
and believe that future model-based trials will not be as
time-consuming for our statistics team. Table 2 summa-
rises issues that cost us valuable time and suggestions on
how to deal with them. This information is not available
in the literature and is learning that we are keen to share
with the community.
Table 2 Issues we faced while designing CHARIOT and suggestions on how to deal with them, based on what we have learnt and
wished we knew before starting the trial design
Area Issue What to do
Software All trial details must be programmed Use existing software to get as close as possible
Funding A great deal of statistical input is
required before the grant is awarded
− This issue is more pronounced for the first few model-based trials that a clinical trials
unit undertakes. Once the process is well-known, code will be in place and templates
will have been designed for text in the protocol and statistical analysis plan
− Consider stating the design without much detail in the grant application. Leave
some aspects of the design to be refined within the grant, during trial set-up
Data management Trial requires fast (e.g., within 24 hours)
and accurate data entry
− Have required data collated on a single case report form
− Accept data during teleconferences (as is done in 3 + 3 designs) and run the
model during the teleconference
− Classify all dose-limiting toxicities as serious adverse events to ensure prompt
reporting
Statistical knowledge − Trial statisticians need to check they
have made good decisions
− Enhance trial statistician learning
– MAST (UK-based)
– Consult colleagues with experience in such designs through a registered clinical
trials unit network
MAST Methodology Advisory Service for Trials
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We held a well-received course for non-statisticians on
how TiTE-CRM works to engage them with the design
and to facilitate future trial meetings. After 10 minutes of
theory, we ran a trial with the attendees as patients using
the statistical software we had developed. Toxicity events
were represented by taking a ball out of a bag and checking
the colour. As well as giving attendees a good idea of how
the trial would work, it also showed that the model could
run in real time and quickly generate dose-escalation
guidance. The attendees also took part in dosing decisions
for patients in the simulated trial, which is valuable practice
for the real decisions that the TMG will need to make
during the actual trial.
Only 6% of early phase trials currently use model-based
methods [10]. To improve uptake, clinical trials units,
particularly those without prior experience, need finance
for statistician salaries, patience and greater input from
their clinicians and more practical guidance in the litera-
ture. At the moment, lack of published guidance means
clinical trial units are having to each reinvent the wheel
when designing their first model-based trial. We need more
publications that explain trials in detail [11–16], more
papers that lead a trial team through the practical steps of
designing a CRM trial, and template and exemplar proto-
cols and statistical analysis plans for teams to start from.
Conclusions
Model-based designs are complex but we found they are
feasible to set up in an academic trials unit. Suitable
guidance on how to implement these studies is needed
to make the process of trial design and set-up easier and
more efficient. We hope that this article describing our
experience and learning in designing a model-based trial
will be a first step in building the needed literature base
to support trial teams.
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